If you live with chronic low back pain, you probably don’t need another promise that sounds too good to be true. You already know what it’s like to rotate through NSAIDs, muscle relaxers, maybe even opioids, and still wake up stiff, sore, and exhausted. That’s why this new phase 3 trial of a standardized cannabis extract for chronic low back pain caught my attention. Not because it’s “magic,” but because the science is finally catching up in a serious way.
In this study, researchers looked at VER-01, a full-spectrum Cannabis sativa extract made from a specific strain (DKJ127) and standardized to a known THC content. More than 800 adults with chronic low back pain that had lasted at least 3 months, and who weren’t getting enough relief from non-opioid meds, were randomized to receive either VER-01 or placebo. On average, participants were in their early 50s, and most had been dealing with pain for a long time. Nature+2PubMed+2
Over 12 weeks, both groups improved (which is common in pain trials), but the VER-01 group did a bit better. Pain scores dropped by about 1.9 points (on a 0–10 scale) in the cannabis group vs about 1.3–1.4 points in the placebo group, with a difference of roughly 0.6 points between them. That may not sound dramatic, but when you look at people who hit meaningful benchmarks, the picture gets clearer: more than half of the people taking VER-01 achieved at least a 30% reduction in pain, compared with about 40% on placebo. The benefit was even larger in those with neuropathic-type pain. PubMed+1
What I really like about this trial is that it didn’t stop at pain scores. Participants also reported better sleep and improved physical function. Sleep quality scores improved more in the VER-01 group, and disability scores on the Roland–Morris questionnaire nudged down in a way that suggests people were actually moving a little better in daily life. For anyone living with chronic low back pain, the combination of “less pain + better sleep + a bit more mobility” often matters more than a single number on a pain scale. Nature+2PubMed+2
The researchers then followed people longer. In the six-month open-label extension, nearly three-quarters of participants reached at least 30% pain reduction, and more than half hit 50%. Importantly, they did not see people chasing higher and higher doses over time. That’s a big deal in a world where opioids often require escalation just to maintain the same level of relief. A second phase 3 trial comparing VER-01 to standard opioid therapy found that the cannabis extract offered slightly better pain reduction over six months, with fewer people stopping treatment and fewer gastrointestinal side effects than the opioid group. SpringerLink+1
Of course, it wasn’t side-effect free. During the titration period, dizziness, sleepiness, and nausea were common. Most of these effects were mild to moderate and tended to improve as people settled into their dose. What stood out is what they didn’t see: there was no clear signal of withdrawal or dependence when people tapered or stopped, and serious adverse events were similar between VER-01 and placebo. That lines up with broader evidence from NIH-linked reviews, which show that non-inhaled cannabinoids for chronic pain often produce modest improvements in pain and function, with higher rates of dizziness, sedation, and nausea, but no strong pattern of organ damage or severe toxicity in the short to medium term. BMJ Open+3NCBI+3NCBI+3
Zooming out for a second, this isn’t the only data set we have. A large systematic review and guideline in The BMJ looked at non-inhaled medical cannabis and cannabinoids for chronic pain (cancer and non-cancer) and concluded that, on average, these products provide small to very small improvements in pain, function, and sleep. Side effects are common but usually manageable. BMJ+2BMJ Open+2 A separate meta-analysis published in PLOS ONE found that cannabinoids reduced chronic pain and improved sleep quality compared with placebo, with effect sizes that were statistically significant but modest. PLOS+1
The National Academies of Sciences, Engineering, and Medicine pulled together a major report in 2017 that still serves as a key reference point. They concluded there is “conclusive or substantial” evidence that cannabis or cannabinoids can help with chronic pain in adults. Psychiatry Online+4National Academies+4NCBI+4 More recent NIH-supported work has continued to refine this picture, suggesting that while the average benefit is modest, some individuals experience meaningful relief, especially when pain has neuropathic features or a strong inflammatory component. At the same time, a JAMA Network Open meta-analysis reminded us that placebo responses in cannabinoid pain trials are large, and media hype can inflate expectations. JAMA Network+2PubMed+2
So what does all of this actually mean for someone living with chronic low back pain who’s curious about cannabis or hemp-based options? To me, it comes down to a few honest points:
- A standardized, carefully dosed cannabis extract like VER-01 can offer real but modest average improvements in pain, sleep, and function, with some people seeing much more benefit than others. Nature+2PubMed+2
- It is not risk-free, but in controlled trials, the main issues tend to be dizziness, sedation, and nausea rather than organ damage or dramatic withdrawal syndromes. Falls, mental health history, and interactions with other medications still need real attention. BMJ Open+3NCBI+3NCBI+3
- It is not a replacement for a good, whole-person plan. The best outcomes in chronic low back pain usually come from combining movement, ergonomics, sleep support, stress management, and sometimes targeted medications or procedures. Cannabis, when it helps, is usually one supportive tool in a larger toolkit, not the entire plan. NCBI+2Health.gov+2
And one more key point: VER-01 in these studies is not the same thing as “whatever CBD or THC product I can find online or at a random shop.” It’s a very specific, GMP-manufactured extract, standardized for THC, derived from a defined cultivar, and used under medical supervision. Real-world products vary a lot in quality, content, and contaminants. That’s why it’s so important to talk with a knowledgeable healthcare professional and to choose products from companies that care about testing, transparency, and patient safety.
From an Herbal IQ perspective, I see this emerging research as encouraging, not because cannabis is perfect, but because it shows what’s possible when we respect the plant, standardize the product, and study it with the same seriousness we give to any other medicine. For someone with long-standing low back pain, a “small” improvement on paper can feel like sleeping a bit deeper, walking a little farther, needing fewer rescue meds, or finally having enough energy to rejoin the parts of life that pain pushed to the side. That matters.
At the same time, I never want you to feel sold to. If you’re exploring plant medicine for pain, sleep, or overall wellness, you deserve clear information, upfront discussion of risks and limits, and space to decide what fits your body and your values. That’s the heart of what we’re trying to do with Herbal IQ: combine good science, lived experience, and genuine care so you can make informed choices.
So, if you’re living with chronic low back pain and you’re curious about where a product like this might fit, the next step isn’t to rush out and buy something. It’s to have a thoughtful conversation: with your provider, with trusted resources, and, if you’d like, with us. Herbal IQ is here to help you sort through the research, understand your options, and support you as you and your care team decide what makes sense for your own wellness journey. No hype, no pressure, just honest education and support.
Referrals / References
- Karst M, et al. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nature Medicine. 2025. Nature+2PubMed+2
- Meissner W, et al. VER-01 vs opioids for chronic low back pain: randomized phase 3 clinical trial. Pain and Therapy. 2025. SpringerLink
- Chou R, et al. Living systematic review on cannabis and other plant-based treatments for chronic pain. AHRQ/NIH evidence reports (2022–2023 updates). Health.gov+3NCBI+3NCBI+3
- Wang L, et al. Medical cannabis or cannabinoids for chronic non-cancer pain: systematic review and guidelines. BMJ. 2021;374:n1034. BMJ+2BMJ Open+2
- Barakji J, et al. Cannabinoids for chronic pain: systematic review, meta-analysis, and trial sequential analysis. PLOS ONE. 2023. PLOS+1
- National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; 2017. Psychiatry Online+4National Academies+4NCBI+4
- Gedin F, et al. Placebo response and media attention in randomized clinical trials of cannabinoids for pain. JAMA Network Open. 2022. JAMA Network+2PubMed+2
- Zeraatkar D, et al. Adverse events associated with medical cannabis for chronic pain: systematic review of non-randomized studies. BMJ Open. 2022. BMJ Open
